Skip to content
PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Immunoscore Colon Cancer Test Included in ESMO Clinical Practice Guidelines Adapted for Pan-Asia
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 5, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced that its Immunoscore Colon Cancer test has been included in the Pan-Asian adapted ESMO 1 Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with localized
View HTML
Toggle Summary New Publication Reinforces Clinical Utility of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 3, 2021-- Veracyte, Inc. (Nasdaq: VCYT) announced today the publication of new long-term clinical utility data showing that the company’s Afirma Genomic Sequencing Classifier (GSC) helped reduce unnecessary surgeries in patients with indeterminate
View HTML
Toggle Summary Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company’s Immuno-Oncology Capabilities
Brightplex technology, acquired from HalioDx , is designed to help drug developers understand and leverage the tumor micro-environment SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 2, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts highlighting the company’s
View HTML
Toggle Summary New Data Demonstrate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier in Tailoring Treatment for Prostate Cancer Patients Experiencing Progression After Surgery
Findings shared today in an oral presentation at ASTRO Annual Meeting 2021 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 26, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced new data demonstrating the clinical utility of the company’s Decipher Prostate genomic classifier for guiding the timing
View HTML
Toggle Summary Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinically High-Risk Prostate Cancer
- First validation of a gene expression classifier in pre-treatment biopsy samples from prospective randomized trials - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 25, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today that new data being presented at the American Society for Radiation
View HTML
Toggle Summary New Data to be Presented at ASTRO 2021 Further Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
- Findings from Analysis Evaluating Test In Newly Diagnosed, Clinically High-Risk Disease to be Highlighted in ASTRO Press Program - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 14, 2021-- Veracyte, Inc. (Nasdaq: VCYT) announced that new data further validating the clinical utility of the
View HTML
Toggle Summary New Publication Demonstrates Ability of Veracyte’s Decipher Bladder Test to Identify Tumors Most Likely to Respond to Chemotherapy
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 13, 2021-- Veracyte, Inc ., (Nasdaq: VCYT) announced today the publication of new data demonstrating that the company’s Decipher Bladder genomic classifier accurately identifies bladder tumors that are most likely to respond to chemotherapy prior
View HTML
Toggle Summary Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 12, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today that it will release its financial results for the second quarter of 2021 after the close of market on Tuesday, November 9 . Company management will host a conference call and webcast to
View HTML
Toggle Summary New Clinical Utility Data Confirm Veracyte’s Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis
Findings to be shared in oral presentation at CHEST Annual Meeting 2021 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 11, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced new data demonstrating that the Envisia Genomic Classifier positively impacts clinical decision-making in idiopathic
View HTML
Toggle Summary Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test’s Ability to Improve Early Lung Cancer Assessment
Company begins making novel, noninvasive test available to limited number of clinical sites to support more timely, accurate lung nodule diagnosis SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 11, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced that new expanded clinical validation data
View HTML